EUVIMEDEUVIMED entdecken
Crossref

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies

Esteban Arrieta-Bolaños iD, Edouard F Bonneville iD, Pietro Crivello iD, Marie Robin iD, Tobias Gedde-Dahl iD, Urpu Salmenniemi iD, Nicolaus Kröger iD, Ibrahim Yakoub-Agha iD, Charles Crawley, Goda Choi, Annoek E C Broers iD, Edouard Forcade und 15 weitere

Journal of Clinical Oncology · 2024-10 · 42 (28) · 3287-3299

DOI: 10.1200/jco.24.00582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-10. Verfasst von Esteban Arrieta-Bolaños und 26 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, HLA Antigens, Graft vs Host Disease. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Human leukocyte antigen (HLA) mismatching can reduce survival of patients with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in HCT practice, in particular graft-versus-host disease (GVHD) prophylaxis by post-transplantation cyclophosphamide (PTCy), influence HLA risk associations is unknown. PATIENTS AND METHODS The study included 17,292 unrelated HCTs with 6-locus high-resolution HLA typing, performed mainly for acute leukemia or related myeloid neoplasms between 2016 and 2020, including 1,523 transplants with PTCy. HLA risk associations were evaluated by multivariable Cox regression models, with overall survival (OS) as primary end point. RESULTS OS was lower in HLA mismatched compared with fully matched transplants (hazard ratio [HR], 1.23 [99% CI, 1.14 to 1.33]; P < .001). This was driven by class I HLA-A, HLA-B, HLA-C (HR, 1.29 [99% CI, 1.19 to 1.41]; P < .001) but not class II HLA-DRB1 and HLA-DQB1 (HR, 1.07 [99% CI, 0.93 to 1.23]; P = .19). Class I antigen-level mismatches were associated with worse OS than allele-level mismatches (HR, 1.36 [99% CI, 1.24 to 1.49]; P < .001), as were class I graft-versus-host peptide-binding motif (PBM) mismatches compared with matches (HR, 1.42 [99% CI, 1.28 to 1.59]; P < .001). The use of PTCy improved GVHD, relapse-free survival compared with conventional prophylaxis in HLA-matched transplants (HR, 0.77 [0.66 to 0.9]; P < .001). HLA mismatching increased mortality in PTCy transplants (HR, 1.32 [1.04 to 1.68]; P = .003) similarly as in non-PTCy transplants (interaction P = .43). CONCLUSION Class I but not class II HLA mismatches, especially at the antigen and PBM level, are associated with inferior survival in contemporary unrelated HCT. These effects are not significantly different between non-PTCy compared with PTCy transplants. Optimized HLA matching should still be considered in modern HCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHematologic NeoplasmsHLA AntigensGraft vs Host DiseaseHistocompatibility TestingHumansMiddle AgedFemaleMaleAdultAdolescentYoung AdultAgedChildCyclophosphamideChild, Preschool

Substanzen

HLA AntigensCyclophosphamide

Autor:innen und Institutionen

  • Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
  • Department of Biomedical Data Sciences, LUMC, Leiden, the Netherlands.
  • EBMT Leiden Study Unit, Leiden, the Netherlands.
  • Saint-Louis Hospital, BMT Unit, Paris, France.
  • Oslo University Hospital, Rikshospitalet, Oslo, Norway.

ORCID-Profile: Esteban Arrieta-Bolaños, Edouard F Bonneville, Pietro Crivello, Marie Robin, Tobias Gedde-Dahl, Urpu Salmenniemi, Nicolaus Kröger, Ibrahim Yakoub-Agha, Annoek E C Broers, Thomas Schroeder, Eric Deconinck, Kristina Carlson, Liesbeth C de Wreede, Florent Malard, Katharina Fleischhauer

Zitieren

APA

Arrieta-Bolaños, E., Bonneville, E. F., Crivello, P., Robin, M., Gedde-Dahl, T., Salmenniemi, U., Kröger, N., Yakoub-Agha, I., Crawley, C., Choi, G., Broers, A. E. C., Forcade, E., Carre, M., Poiré, X., Huynh, A., Lenhoff, S., Ciceri, F., Tholouli, E., Schroeder, T., …, & Cellular Therapy and Immunobiology Working Party of the EBMT (2024). Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 42(28), 3287-3299. https://doi.org/10.1200/jco.24.00582

Vancouver

Arrieta-Bolaños E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, et al. Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology. 2024;42(28):3287-3299. doi:10.1200/jco.24.00582

BibTeX
@article{ArrietaBolaos2024,
  author = {Arrieta-Bolaños, Esteban and Bonneville, Edouard F and Crivello, Pietro and Robin, Marie and Gedde-Dahl, Tobias and Salmenniemi, Urpu and Kröger, Nicolaus and Yakoub-Agha, Ibrahim and Crawley, Charles and Choi, Goda and Broers, Annoek E C and Forcade, Edouard and Carre, Martin and Poiré, Xavier and Huynh, Anne and Lenhoff, Stig and Ciceri, Fabio and Tholouli, Eleni and Schroeder, Thomas and Deconinck, Eric and Carlson, Kristina and de Wreede, Liesbeth C and Hoogenboom, Jorinde D and Malard, Florent and Ruggeri, Annalisa and Fleischhauer, Katharina and Cellular Therapy and Immunobiology Working Party of the EBMT, Cellular Therapy and Immunobiology Working Party of the EBMT},
  title = {Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {28},
  pages = {3287--3299},
  doi = {10.1200/jco.24.00582}
}
Kostenlos starten →